Laureate Biopharmaceutical Services Inc., a contract development and manufacturing company, has added James Utterback to its board. Utterback was most recently president, chief executive and director of M2Gen, part of the Moffitt Cancer Center in Tampa. Laureate is a portfolio company of Saints Capital.
Laureate Biopharmaceutical Services, Inc. a full-service biopharmaceutical contract development and manufacturing organization, today announced the appointment of James D. Utterback to the company’s Board of Directors.
“Jim is an invaluable addition to our board, and we are fortunate to have access to his deep industry knowledge,” said Michael A. Griffith, Chief Executive Officer.
“Jim has more than 30 years of leadership experience building successful startups and public organizations in healthcare software, products and services globally. He has consistently innovated new approaches to growth and his customer-driven business philosophies complement Laureate’s quality-focused right-first-time model.”
Mr. Utterback most recently served as President, Chief Executive Officer and Board Member of M2Gen, part of the Moffitt Cancer Center in Tampa, Florida, and the third largest oncology academic medical research center in the U.S. He is Founder and Chairman of RxCeL Partners LLC, a healthcare consulting firm based in Philadelphia and Tampa. Mr. Utterback also held positions as Chief Executive Officer of SCIREX Corporation (now Premier Research), and President of the Pharmaceutical Division of Vivo Metrics, a global leader in ambulatory data collection. Earlier in his career, he was a Corporate Officer at Sanofi (then RPR) in Paris, France, and at Covance in Princeton, NJ. Mr. Utterback started his career at GE’s Medical Systems Division. He earned a Master of Science in Industrial Psychology from Virginia Polytechnic Institute, and a Bachelor of Science in Psychology/Economics from Washington & Lee University.
About Laureate Biopharmaceutical Services, Inc.
Laureate Biopharmaceutical Services, Inc. is a full-service biopharmaceutical contract development and manufacturing organization. Laureate Biopharma’s scientists are expert in process development and cGMP production of therapeutic proteins, including monoclonal antibodies and Fc-fusion proteins. In addition, the company’s portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and regulatory support. Laureate Biopharma has served a global client base from its Princeton, New Jersey facility since 1981, and is a portfolio company of Saints Capital, LLC. For more information related to Laureate Biopharma’s capabilities and ongoing improvements, please visit www.LBioS.com
About Saints Capital, LLC
Saints Capital is a leading direct secondary acquirer of venture capital and private equity investments in emerging growth companies around the globe. It also makes traditional direct venture capital investments on a primary basis and, in special situations, in technology, healthcare, consumer and industrial companies in the United States. Founded in 2000, Saints provides liquidity for private investors in such markets as investment and commercial banks, buyouts, corporate venture capital and hedge funds. Saints has more than $1 billion of committed capital under management, over 50 completed portfolio transactions and investments in more than 200 companies.